ArticleInvestigational new drugs2014
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
James M Cleary et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
42 papers cite it
this papercites it